US Patent

US10265287 — Methods of reducing triglycerides and LDL-C

Method of Use · Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2030-04-29 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

USPTO Abstract

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Drugs covered by this patent

Vascepa (ICOSAPENT ETHYL) · Amarin Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2700`	—	Vascepa
`U-2700`	—	Vascepa

Patent Metadata

Patent number: US10265287
Jurisdiction: US
Classification: Method of Use
Expires: 2030-04-29
Drug substance claim: No
Drug product claim: No
Assignee: Amarin Pharmaceuticals Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.